ARTICLE | Company News
ExonHit, OSEO cancer news
June 11, 2012 7:00 AM UTC
ExonHit said it received €1.9 million ($2.4 million) in funding under the Strategic Industrial Innovation program from France's OSEO agency. The funding was awarded for ExonHit's participation in a consortium to develop therapies to treat chemo- and radio-resistant cancers and tools to enable personalized care. ExonHit will use its Genome Wide SpliceArray (GWSA) technology to study tumor transcriptomic profiles and identify biomarkers of therapeutic response. The company will also be responsible for developing an enzymatic therapy companion diagnostic to identify responders. ExonHit already received €1.1 million ($1.4 million) from OSEO when the project began in January. ExonHit's technology identifies RNA splice variants. ...